FRANKFURT (Reuters) -CureVac and GSK's second-generation vaccine candidate targeting two recent COVID-19 variants has been shown to be highly effective in preclinical studies on mice, CureVac said, as ...
MUNICH (Reuters) - A German court on Tuesday invalidated a patent that was the basis of a patent violation lawsuit brought by CureVac against its domestic rival BioNTech, in a blow to CureVac's claims ...
Enrollment completed for Phase 2 COVID-19 study with mono- and bivalent vaccine candidates; study on track for data read-out in early 2024 First participant dosed in seasonal flu Phase 2 study with ...
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 15, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on ...
CureVac N.V. (NASDAQ:CVAC), a biopharmaceutical company specializing in mRNA-based therapies and vaccines with a market capitalization of $818.75 million, stands at a critical juncture in its ...
With more than a touch of inevitability, CureVac is abandoning its first mRNA COVID vaccine after dismal results earlier this year and switching focus to a second mRNA asset with GlaxoSmithKline. A ...
CureVac’s first-generation COVID vaccine—a shot that failed to reach anywhere near the high efficacy bar set by rivals—is continuing to drag on the German biotech’s earnings and is expected to ...
A German court has dealt the first blow against CureVac amid the company's heated COVID-19 vaccine patent fight with fellow German mRNA specialist BioNTech. The German Federal Patent Court ruled that ...
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 15, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results